Booker arrives at the Dallas-based company with a background spanning L'Oréal, Pfizer Consumer Healthcare, and Procter & Gamble. His career trajectory, which began in laboratory science, informs a marketing philosophy centered on evidence-based brand building. CEO Lisa Paley noted that Booker’s capacity to translate clinical findings into accessible communication will be vital for the brand’s expansion into longevity-focused skincare.

In his new capacity, Booker will oversee both professional channels—including physician partnerships and med spas—and direct-to-consumer platforms. He is expected to prioritize AI-driven digital acceleration and modernize go-to-market strategies. This transition aligns with Revision Skincare’s broader focus on the Dermal-Epidermal Junction, a segment the company identifies as the 'Longevity Layer,' requiring specialized, bioavailable formulations for long-term skin health.